AML with FLT3-ITD mutations show increased sensitivity to increasing doses of ibrutinib compared to non-FLT3 mutated AML (Fig. 1A), Similar experiments in AML cell lines shows that MV4–11 (FLT3-ITD), but not OCI-AML3 or THP-1 (non- FLT3-ITD), have reduced survival in response to increasing concentrations of ibrutinib up to a maximum of 5000 nM (Fig. 1B). Here, FLT3 is linked to acute myeloid leukemia.